Philipps-Universität Marburg

Nilotinib Vs Nilotinib Plus Pegylated Interferon a (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response (2019) Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Brummendorf TH, Rosee PL, Heim D, et al. Conference contribution Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia (2019) Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Sauer T, et al. Journal article β-Secretase BACE1 Is Required for Normal Cochlear Function (2019) Dierich M, Hartmann S, Dietrich N, Möser P, Brede F, Johnson Chacko L, Tziridis K, et al. Journal article First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: A retrospective observational multicentre study (2019) Menzler K, Mross PM, Rosenow F, Schubert-Bast S, Willems LM, Zahnert F, Immisch I, et al. Journal article S2k Guideline: Diagnosis in case of suspected Betalactam Antibiotic Hypersensitivity (2019) Wurpts G, Aberer W, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, et al. Journal article Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group (2019) Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, et al. Journal article Changing the perception of premenstrual dysphoric disorder - An online-experiment using the Stereotype Content Model (2019) Janda C, Asbrock F, Herget M, Kues JN, Weise C Journal article Deficiencies in the Mitochondrial Electron Transport Chain Affect Redox Poise and Resistance Toward Colletotrichum higginsianum (2019) Mccollum C, Geisselsoeder S, Engelsdorf T, Voitsik AM, Voll L Journal article KCNQ1 an unexpected mediator of cold avoidance (2019) Kiper AK, Wegner S, Kadala A, Bertoune MAR, Touska F, Matschke V, Wrobel E, et al. Conference contribution KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. Conference contribution